/library/oar/handle/123456789/39051 2026-05-25T20:54:35Z 2026-05-25T20:54:35Z Vella Briffa, Dino /library/oar/handle/123456789/13555 2019-10-29T10:19:17Z 2004-01-01T00:00:00Z

Title: The scaly scalp Authors: Vella Briffa, Dino Abstract: A popular atlas of dermatology lists more than 35 diseases which commonly affect the scalp.1 Scaling is a prominent feature of several of them. Clearly, a comprehensive review is not possible within the compass of this article. Instead, attention will be focused on some relatively common conditions, which the community pharmacist may be called upon to recognize and treat. The discussion includes advice concerning diagnoses, pitfalls, over-the-counter (OTC) remedies, and when to refer.

2004-01-01T00:00:00Z Anastasi, Tessa /library/oar/handle/123456789/13554 2019-10-29T10:19:45Z 2004-01-01T00:00:00Z

Title: The AD/HD family support group Authors: Anastasi, Tessa Abstract: Attention Deficit Hyperactivity Disorder is still a diagnosis which raises many questions. Is it a bona fide diagnosis or not?

2004-01-01T00:00:00Z Bowman, Corinne /library/oar/handle/123456789/13552 2019-10-29T10:20:12Z 2004-01-01T00:00:00Z

Title: Drugs in renal failure Authors: Bowman, Corinne Abstract: When prescribing a drug for a patient with renal failure, many issues must be considered before giving any advice or recommending any dosage changes in such a condition. This is one of the problems tackled by medicine information pharmacists. A drug may behave differently in a patient with renal dysfunction from a patient with normal function. This article helps to highlight some of the basic principles that we need to keep in mind when dealing with information about drugs in renal disease.

2004-01-01T00:00:00Z Sant Fournier, Mary Ann /library/oar/handle/123456789/13548 2019-10-29T10:20:43Z 2004-01-01T00:00:00Z

Title: Equity and solidarity in healthcare : a patient-centred pharmaceutical model Authors: Sant Fournier, Mary Ann Abstract: The perceived application of the principles of Equity and Solidarity in healthcare has been amply debated over the years, nationally and internationally, particularly in the context of the allocation of resources. It is a consideration of grave concern to various stakeholders. It is significant, that at this moment in time, a time of change, opportunities and challenges, both nationally and globally, are addressed from a bioethical dimension, with a pharmaceutical perspective and a patient - centered focus. In this ambit the pharmaceutical model to counter inequality of access to pharmaceutical services is presented.

2004-01-01T00:00:00Z